A5010687642- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Antifungal resistance and susceptibility
- Gut microbiota and health
- COVID-19 Impact on Reproduction
- COVID-19 and healthcare impacts
- Viral Infections and Outbreaks Research
- Long-Term Effects of COVID-19
- Clostridium difficile and Clostridium perfringens research
- Antimicrobial Resistance in Staphylococcus
- Viral Infections and Vectors
- Disaster Response and Management
- Burkholderia infections and melioidosis
- Fungal Infections and Studies
- Herpesvirus Infections and Treatments
- Bacterial Identification and Susceptibility Testing
- Hepatitis B Virus Studies
- Parvovirus B19 Infection Studies
- SARS-CoV-2 detection and testing
- Cancer Immunotherapy and Biomarkers
- Pneumonia and Respiratory Infections
- Bacillus and Francisella bacterial research
- Streptococcal Infections and Treatments
Ben-Gurion University of the Negev
2018-2025
Assuta Medical Center
2018-2025
Soroka Medical Center
2021
Israel Ministry of Health
2015-2021
Clalit Health Services
2021
Faculty of Public Health
2020
Israel Defense Forces Medical Corps
2008-2019
Sheba Medical Center
2017
Tel Aviv Sourasky Medical Center
2008-2017
Tel Aviv University
2004-2015
New fecal microbiota for cancer patients The composition of the gut microbiome influences response to immunotherapies. Baruch et al. and Davar report first-in-human clinical trials test whether transplantation (FMT) can affect how metastatic melanoma respond anti–PD-1 immunotherapy (see Perspective by Woelk Snyder). Both studies observed evidence benefit in a subset treated patients. This included increased abundance taxa previously shown be associated with anti–PD-1, CD8 + T cell...
Following low incidence of respiratory syncytial virus (RSV) infections in 2020 during the COVID-19 pandemic, we noted a resurgence hospitalised children spring/summer 2021 following relaxation public health measures. We compared this outbreak to previous autumn/winter seasons. found higher weekly case numbers and rates, more cases from urban neighbourhoods with lower socioeconomic status, similar clinical presentation severity. Public implications include re-evaluation palivizumab...
Abstract Resistance of SARS-CoV-2 to antivirals was shown develop in immunocompromised individuals receiving remdesivir. We describe an patient who treated with repeated and prolonged courses nirmatrelvir developed de-novo E166V/L50F mutations the Mpro region. These were associated clinical virological treatment failure.
Environmental surfaces have been suggested as likely contributors in the transmission of COVID-19. This study assessed infectivity severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contaminating and objects two hospital isolation units a quarantine hotel.
BackgroundWe assessed outcome of patients with moderate and severe COVID-19 following treatment convalescent plasma (CP) the association IgG levels in transfused CP.MethodsA prospective cohort study. Primary was improvement at day 14 defined as alive, not on mechanical ventilation, moderate, mild, or recovered from COVID-19. Antibody CP units were unknown time treatment. against spike protein S1 subsequently measured by ELISA. Neutralizing antibodies titers determined a subset. Outcome...
Waning immunity and an increased incidence of coronavirus disease 2019 (COVID-19) during the Omicron outbreak led Israeli Ministry Health to recommend a fourth vaccine dose for high-risk individuals. In this study, we assessed its effect hospitalized patients with severe breakthrough COVID-19.In multicenter cohort study adults COVID-19 in Israel, from 15 31 January 2022, cases were divided according number vaccinations received. Poor outcome was defined as mechanical ventilation or...
The coronavirus disease 2019 global pandemic is reshaping our understanding of medicine, including the diagnostic approach to common medical presentations. We describe a novel case 3-year-old male with clinical diagnosis Henoch–Schonlein Purpura vasculitis concurrent SARS-CoV-2 infection. This highlights potentially newly described presentation
Humoral responses to coronavirus disease 2019 (COVID-19) vaccines in hemodialysis (HD) patients can direct vaccination policy.We compared 409 COVID-19-naïve HD from 13 units Israel 148 non-dialysis-dependent controls. Twenty-four previously infected (antinucleocapsid positive) were analysed separately. Blood samples obtained ≥14 days post-vaccination (BNT162b2, Pfizer/BioNTech) assess seroconversion rates and titers of anti-spike (anti-S) neutralizing antibodies.The median time blood sample...
Hematological malignancy (HM) patients treated with anti-CD20 monoclonal antibodies are at higher risk for severe COVID-19. A previous single-center study showed worse outcomes in obinutuzumab compared to rituximab. We examined this hypothesis a large international multicenter cohort.
ABSTRACT Background Available data on combat wound‐related invasive mould infections (IMIs) are limited. Objectives We aimed to describe the characteristics and outcomes of IMIs in casualties a recent conflict. Patients/Methods A retrospective study including hospitalised patients with combat‐related injuries, fulfilling criteria for IMI based Trauma Infectious Disease Outcomes Study definitions. Patient injury characteristics, management described compared previous cohorts. Mould isolates...
Pulmonary exposure to the plant toxin ricin, leads respiratory insufficiency and death. To date, in-depth study of functional disorders ensuing pulmonary intoxication, a prerequisite for establishing clinically-relevant therapeutic protocol, is hampered by lack an appropriate animal model. this end, we set up pig, as large model comprehensive multifarious clinical manifestations ricinosis. Here report first time, monitoring barometric whole body plethysmography function tests in...
Abstract Background Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive disease (IPD) rates declined children, with variable indirect impact on adults. Methods A population-based, prospective, nationwide active surveillance of IPD Israel, 2004–2019 (for adults ≥18 years, 2009–2019). The 7-valent PCV (PCV7)/PCV13 were implemented Israel July 2009/November 2010, respectively, >90% uptake children <2...
We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The analyzed data from 14 who received combination tixegavimab/cilgavimab and antiviral medications. Response was evaluated based symptom improvement, PCR cycle-threshold values, C-responsive protein levels. Eleven achieved complete clinical virological resolution, while three showed partial responses. suggests potential association between non-response neutralization....
It is unknown whether convalescent immunoglobulins (cIgGs) are better than plasma (CP) for patients with coronavirus 2019 (COVID-19).In this randomized controlled trial, we assigned high risk COVID-19 ≤10 days of symptoms, to receive cIgGs or CP. The primary endpoint was improvement on day 14 according the World Health Organization scale. Secondary endpoints were survival 14, and improvement, survival, percent ventilated 28, treatment response in unvaccinated vaccinated patients.A total 319...
Abstract Background The Accelerate PhenoTest® BC system (AXDX) is a novel assay for rapid bacterial identification and antimicrobial susceptibility (AST). We report an evaluation of its impact on treatment patients with Gram-negative bacteremia (GNB) high risk resistance (AMR). Methods A prospective single-center before after implementation AXDX in addition to standard-of-care (SOC) microbiology stewardship program (ASP). Patients GNB reported during laboratory working hours prespecified...
Abstract Background Little is known about the risk of progression from carbapenemase-producing Enterobacterales (CPE) carriage to CPE bloodstream infection (BSI) outside high-risk settings. We aimed determine incidence BSI among carriers and assess whether differs by carbapenemase, species, setting. Methods conducted a nationwide population-based retrospective cohort study using national databases. The consisted all patients in Israel with detected screening 1 January 2020 10 October 2022....